WO2005021741A3 - Agents diagnostiques et therapeutiques pour maladies associees a la kallicreine 11 (klk11) - Google Patents

Agents diagnostiques et therapeutiques pour maladies associees a la kallicreine 11 (klk11) Download PDF

Info

Publication number
WO2005021741A3
WO2005021741A3 PCT/EP2004/009210 EP2004009210W WO2005021741A3 WO 2005021741 A3 WO2005021741 A3 WO 2005021741A3 EP 2004009210 W EP2004009210 W EP 2004009210W WO 2005021741 A3 WO2005021741 A3 WO 2005021741A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
klk11
kallikrein
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/009210
Other languages
English (en)
Other versions
WO2005021741A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Stefanie Polej
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Stefanie Polej
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Stefanie Polej filed Critical Bayer Healthcare Ag
Priority to EP04764200A priority Critical patent/EP1664290A2/fr
Publication of WO2005021741A2 publication Critical patent/WO2005021741A2/fr
Publication of WO2005021741A3 publication Critical patent/WO2005021741A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une KLK11 humaine qui est associée aux maladies cardiovasculaires, aux maladies urologiques, aux maladies endocrinologiques, aux maladies métaboliques, aux troubles de la reproduction, aux maladies dermatologiques, aux maladies respiratoires, aux maladies gastroentérologiques et aux problèmes cancéreux. L'invention concerne également des dosages permettant d'identifier des composés utiles dans le traitement ou la prévention de maladies cardiovasculaires, de maladies urologiques, de maladies endocrinologiques, de maladies métaboliques, de troubles de la reproduction, de maladies dermatologiques, des maladies respiratoires, de maladies gastroentérologiques et de problèmes cancéreux. L'invention concerne en outre des composés qui se fixent à et/ou activent ou inhibent l'activité de la KLK11 ainsi que des compositions pharmaceutiques comprenant lesdits composés.
PCT/EP2004/009210 2003-08-30 2004-08-17 Agents diagnostiques et therapeutiques pour maladies associees a la kallicreine 11 (klk11) WO2005021741A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04764200A EP1664290A2 (fr) 2003-08-30 2004-08-17 Agents diagnostiques et therapeutiques pour maladies associees a la kallicreine 11 (klk11)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03019801.4 2003-08-30
EP03019801 2003-08-30

Publications (2)

Publication Number Publication Date
WO2005021741A2 WO2005021741A2 (fr) 2005-03-10
WO2005021741A3 true WO2005021741A3 (fr) 2005-07-07

Family

ID=34259155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/009210 WO2005021741A2 (fr) 2003-08-30 2004-08-17 Agents diagnostiques et therapeutiques pour maladies associees a la kallicreine 11 (klk11)

Country Status (2)

Country Link
EP (1) EP1664290A2 (fr)
WO (1) WO2005021741A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055702A2 (fr) * 2000-10-26 2002-07-18 Curagen Corp Protéines humaines, polynucléotides les codant et procédés d'utilisation correspondants
WO2002097438A1 (fr) * 2001-05-25 2002-12-05 Mount Sinai Hospital Methode de detection et de surveillance des cancers de la prostate et de l'ovaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055702A2 (fr) * 2000-10-26 2002-07-18 Curagen Corp Protéines humaines, polynucléotides les codant et procédés d'utilisation correspondants
WO2002097438A1 (fr) * 2001-05-25 2002-12-05 Mount Sinai Hospital Methode de detection et de surveillance des cancers de la prostate et de l'ovaire

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MERLO C. ET AL.: "Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease.", ATHEROSCLEROSIS, vol. 161, 2002, pages 261 - 267, XP002316792 *
NAKAMURA T. ET AL.: "Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues.", UROLOGY, vol. 61, no. 5, May 2003 (2003-05-01), pages 1042 - 1046, XP002316790 *
YU H. ET AL.: "Association of the tissue kallikrein gene promoter with ESRD and hypertension.", KIDNEY INT., vol. 61, 2002, pages 1030 - 1039, XP002316791 *

Also Published As

Publication number Publication date
EP1664290A2 (fr) 2006-06-07
WO2005021741A2 (fr) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2004104216A3 (fr) Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2005022146A3 (fr) Diagnostics et traitements de maladies associees a la kallikreine 13 (klk13)
WO2005114207A3 (fr) Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2005100990A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
WO2005078117A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6)
WO2004097358A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la serine protease 2 transmembranaire humaine (tmprss2)
WO2005022164A3 (fr) Agents diagnostiques et agents therapeutiques destines a des maladies associees a la kallikreine 8 (klk8)
WO2005075662A3 (fr) Methodes diagnostiques et therapeutiques des maladies associees au kallikrein 2 (klk2)
WO2005118840A3 (fr) Elements diagnostiques therapeutiques pour des maladies associees a la kallikreine 10 (klk10)
WO2005085466A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 2 associee a rho (rock2)
WO2005075675A3 (fr) Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1)
WO2005090994A3 (fr) Diagnostic et therapeutique pour des maladies associees a la proteine kinase, dependante de cgmp, type 1 (prkg1)
WO2005090966A3 (fr) Diagnostic et therapeutique pour des maladies associees au recepteur delta active de la proliferation des peroxysomes (ppard)
WO2004097034A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la serine protease 4 transmembranaire humaine (tmprss4)
WO2005021741A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la kallicreine 11 (klk11)
WO2005095953A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 6 (ccr6)
WO2005085469A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 1 associee a rho (rock1)
WO2006013016A3 (fr) Diagnostics et therapeutique pour maladies liees a la serine protease eosinophile 1 (prss21)
WO2005040401A3 (fr) Diagnostic et traitement de maladies associees a la serine-protease mosaique (msp)
WO2006013013A3 (fr) Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb)
WO2004104595A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la x-pro dipeptidase (pepd)
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)
WO2005040792A3 (fr) Diagnostics et therapeutiques pour des maladies associees a l'arginyl aminopeptidase (aminopeptidase b)-de type 1 (rnpepl1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004764200

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004764200

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004764200

Country of ref document: EP